Cycles N8 + N5 + N6

The regimen "Cycles N8 + N5 + N6" refers to a specific chemotherapy protocol used in the treatment of high-risk neuroblastoma. This is a combination chemotherapy approach that consists of three different chemotherapy cycles administered sequentially. ## Components and Administration The regimen consists of: 1. N8 cycles containing topotecan and cyclophosphamide 2. N5 cycles 3. N6 cycles This combination is part of induction chemotherapy for high-risk neuroblastoma patients. The search results indicate this is an experimental induction chemotherapy regimen that includes two additional topotecan-based cycles (N8) followed by the standard N5-N6 cycles[1][3]. ## Clinical Trial Information This regimen was evaluated in clinical trials, including the SIOPEN High-Risk Neuroblastoma Study 2 (SIOPEN/HR-NBL2)[1][3]. According to the search results, the trial was expected to have final results in 2020[1]. ## Treatment Schedule The treatment follows a specific schedule with evaluations performed after certain cycles: - N5 cycle 1 - N6 cycle 2 - Evaluation after 2nd cycle - N5 cycle 3 - N6 cycle 4 - Evaluation after 4th cycle - N5 cycle 5 - N6 cycle 6[3] ## Supportive Care Antiemetic drugs are strongly recommended for the N5 and N6 cycles. Specifically, ondansetron bolus 4 mg/m² followed by continuous ondansetron infusion 16 mg/m²×d is recommended[6]. ## Treatment Context This chemotherapy regimen is part of a broader treatment approach for high-risk neuroblastoma that typically includes: - Induction chemotherapy (including the N8+N5+N6 cycles) - Surgery - Consolidation therapy (high-dose chemotherapy with autologous stem cell rescue) - Local control (radiation therapy) - Maintenance therapy (including immunotherapy and retinoic acid)[1][3] The regimen is specifically used in the induction phase of treatment, which aims to reduce tumor burden before proceeding to other treatment modalities.